Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0257
ORIGINAL RESEARCH
|
Discovering novel genes and druggable mutations in gastric cancer by applying Next-Generation Sequencing. |
Prof. Theodore Liakakos, MD, PhD
|
Affiliation: Theodore Liakakos, MD, Professor of Surgery, Head of 1st Department of Surgery, National Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
E-mail: theodlia@otenet.gr |
Abstract
Background: Slow progress in understanding molecular mechanisms of tumorigenesis, metastasis and therapeutic resistance are reflected by substantially cancer-related death-rates in stages II, III and IV.
Methods: Rapid progress and validity of Next-Generation Sequencing (NGS) to identify genetic heterogeneity has led us to perform whole exome sequencing (WES) – normal – cancer tissue paired in gastric cancer patients. Aim of this study was to identify novel cancer driver genes and mutations with clinical revelation.
Results: Several new gastric cancer driver genes and mutations have been highlighted by our statistical analysis. Two of these genes might have clinical implications as biomarkers and/or druggable mutations.
Conclusion: Large patient – centric WES trials are required for valid identification of novel oncotarget – based drug development and new predictive biomarkers. This strategy could improve personalized treatment of gastric cancer.
(Citation: Gastric & Breast Cancer 2017; 12(1):
20-30)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 25 February 2017 |
|
